Evidence map›Paper›PMID 38844774›Full record

ArticleScientific reports2024

Genomic profiles of Japanese patients with vulvar squamous cell carcinoma.

Erisa Fujii, Mayumi Kobayashi Kato, Maiko Yamaguchi, Daiki Higuchi, Takafumi Koyama, Masaaki Komatsu, Ryuji Hamamoto, Mitsuya Ishikawa, Tomoyasu Kato, Takashi Kohno and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Erisa FujiiDivision of Genome Biology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Mayumi Kobayashi KatoDivision of Genome Biology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Maiko YamaguchiDivision of Genome Biology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Daiki HiguchiDivision of Genome Biology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Takafumi KoyamaDepartment of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
Masaaki KomatsuDivision of Medical AI Research and Development, National Cancer Center Research Institute, Tokyo, Japan.
Ryuji HamamotoDivision of Medical AI Research and Development, National Cancer Center Research Institute, Tokyo, Japan.
Mitsuya IshikawaDepartment of Gynecology, National Cancer Center Hospital, Tokyo, Japan.
Tomoyasu KatoDepartment of Gynecology, National Cancer Center Hospital, Tokyo, Japan.
Takashi KohnoDivision of Genome Biology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Kouya ShiraishiDivision of Genome Biology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. kshirais@ncc.go.jp.
Hiroshi YoshidaDepartment of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan. hiroyosh@ncc.go.jp.

Funding

a Grant-in-Aid for Scientific Research (B) 20H03695a Grant-in-Aid for Scientific Research (C) 22K09563Grant-in-Aid for Scientific Research (C) 19K16572Grant-in-Aid for Young Scientists (B) 20K18207the National Cancer Center Research and Development Fund 2023-J-2
6 · The paper itself

Abstract

The incidence of vulvar carcinoma varies by race; however, it is a rare disease, and its genomic profiles remain largely unknown. This study examined the characteristics of vulvar squamous cell carcinoma (VSCC) in Japanese patients, focusing on genomic profiles and potential racial disparities. The study included two Japanese groups: the National Cancer Center Hospital (NCCH) group comprised 19 patients diagnosed between 2015 and 2023, and the Center for Cancer Genomics and Advanced Therapeutics group comprised 29 patients diagnosed between 2019 and 2022. Somatic mutations were identified by targeted or panel sequencing, and TP53 was identified as the most common mutation (52-81%), followed by HRAS (7-26%), CDKN2A (21-24%), and PIK3CA (5-10%). The mutation frequencies, except for TP53, were similar to those of Caucasian cohorts. In the NCCH group, 16 patients of HPV-independent tumors were identified by immunohistochemistry and genotyping. Univariate analysis revealed that TP53-mutated patients were associated with a poor prognosis (log-rank test, P = 0.089). Japanese VSCC mutations resembled those of Caucasian vulvar carcinomas, and TP53 mutations predicted prognosis regardless of ethnicity. The present findings suggest potential molecular-targeted therapies for select VSCC patients.

Indexed as

Carcinoma, Squamous CellMutationTumor Suppressor Protein p53Vulvar NeoplasmsAdultAgedAged, 80 and overClass I Phosphatidylinositol 3-KinasesCyclin-Dependent Kinase Inhibitor p16East Asian PeopleFemaleGenomicsHumansJapanJapanese peopleMiddle AgedCDKN2A protein, humanClass I Phosphatidylinositol 3-KinasesCyclin-Dependent Kinase Inhibitor p16HRAS protein, humanPIK3CA protein, humanProto-Oncogene Proteins p21(ras)TP53 protein, humanTumor Suppressor Protein p53Genomic profilingHuman papillomavirusPrognosisTP53 mutationVulvar squamous cell carcinoma

Identifiers

PMID38844774
PMCPMC11156893

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.